黑料正能量

Global Drug Discovery Market Trends and Insights

AI-Driven Target Identification Gains Mainstream Adoption

Generative platforms reduced target-to-hit timelines by up to half during 2024-2025, as shown by TuneLab, which relied on large language models to predict binding affinities and ADMET profiles. Xaira Therapeutics demonstrated the commercial traction of this approach by announcing its first oncology candidate only 14 months after founding. NVIDIA joined forces with Eli Lilly in a USD 1 billion initiative that combines genomic and proteomic datasets to pinpoint novel targets in metabolic and neurodegenerative diseases.^{[1]NVIDIA Corporation, 鈥淟illy and NVIDIA to Build AI Drug Discovery Lab,鈥� nvidia.com} Start-ups such as Chai Discovery and Genesis Therapeutics attracted USD 130 million and USD 200 million, respectively, in 2024, validating the appetite for transformer-based models that flag off-target liabilities early. The FDA issued draft guidance in 2025 that requires sponsors to document model provenance, favoring platforms with transparent data pipelines.

Rising Biologics Pipeline Complexity Boosts Outsourced Discovery

Biologics accounted for 38.28% of drug-type revenue in 2025 and are projected to grow at 8.18% through 2031, driven by antibody-drug conjugates, bispecific formats, and cell therapies that require specialized infrastructure. Contract development and manufacturing organizations responded by adding capacity; WuXi Biologics commissioned 12,000 liters of bioreactor volume in Ireland, while Lonza opened a USD 400 million facility in Singapore to support antibody discovery. High costs for post-translational optimization and immunogenicity testing have driven many sponsors to partner with external providers that maintain validated expression systems. With biologics requiring greater discovery investment yet enjoying higher clinical success rates, the economic rationale for outsourcing is growing stronger.

Venture-Capital Funding Surge for Platform Biotech

Platform biotech firms raised USD 3.2 billion across 22 early-stage rounds during 2024-H1 2025, more than doubling the capital deployed in the prior 18 months. Investors back the idea that AI-native discovery can serve several sponsors at once, capturing services revenue while retaining equity upside in each candidate. Chai Discovery, Genesis Therapeutics, Excelsior Oncology, and Basecamp Research together raised over USD 485 million to build proprietary libraries and secure high-performance compute clusters. The ability to integrate multimodal datasets, genomic, transcriptomic, and clinical, has become the decisive pitch for investors seeking scalable platforms.

Accelerated FDA Fast-Track Designations for Rare-Disease Assets

Fast-track designations climbed to 45 in 2024, compressing regulatory timelines through rolling review and more frequent sponsor meetings.^{[2]U.S. Food and Drug Administration, 鈥淔ast Track Designation Statistics 2024,鈥� fda.gov} The U.S. Orphan Drug Act, which provides seven-year market exclusivity and sizeable tax credits, continues to steer discovery toward diseases affecting fewer than 200,000 patients. The European Medicines Agency granted 89 orphan designations the same year, while Japan introduced a conditional pathway that accepts single-arm trials for ultra-rare conditions. These synchronous reforms encourage sponsors to file in multiple regions with one data package, shaving months off commercialization timelines.

Escalating Discovery Costs Amid Macro-Inflationary Pressure

Discovery spending per candidate rose between 8% and 12% from 2023 to 2025 as wages for specialist scientists increased and reagent supply chains tightened. Smaller biotechs with market capitalizations below USD 500 million felt the squeeze most acutely; 18 such firms exited the market in 2024 because they could not fund programs to investigational new drug filing. Contract research organizations also raised fees as they encountered higher utility and instrumentation costs, and sponsors with pre-inflation agreements saw immediate margin erosion. Many firms now consolidate work with fewer vendors and relocate early-stage activities to lower-cost science parks in India and Eastern Europe.

Clinical Translation Failures in Novel Modalities

Gene and cell therapies continue to show high attrition in human studies. Bluebird Bio paused its sickle-cell gene therapy in 2024 after two patients developed myelodysplastic syndrome, while uniQure halted a Huntington鈥檚 program following adverse events. An analysis in Nature Biotechnology found that gene-therapy approval rates were only 6% for candidates entering Phase I between 2015-2023, roughly half the success rate for small molecules.^{[3]Nature Biotechnology, 鈥淕ene Therapy Attrition Rates,鈥� nature.com/nbt} Manufacturing challenges add further risk, since both auto黑料正能量us CAR-T runs and allogeneic platforms require extensive pre-clinical validation, extending discovery timelines by as much as a year.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Process Phase: Pre-Clinical Validation Becomes the Focal Point

Hit generation and high-throughput screening commanded 36.02% of 2025 revenue, demonstrating the capital intensity of robotic liquid handlers and compound warehouses that dominate early discovery. Sponsors acknowledge, however, that physical assays alone cannot sustain speed in the drug discovery market, so virtual screens now filter libraries before reagents are consumed. Target identification and validation, roughly 22% of spend, benefits from consortia that release validated chemical probes, reducing redundant experiments. Lead optimization, about 28% of budgets, now couples structure鈥揳ctivity relationships with AI-guided ADMET profiling to mitigate downstream failure risk. 

Pre-clinical candidate selection is the only phase projected to outpace the overall drug discovery market at a 7.06% CAGR, reflecting pressure to enter the clinic with greater confidence. Charles River Laboratories expanded its capacity in the United Kingdom and China by 15% to offer integrated toxicology, pharmacokinetics, and formulation packages. Thermo Fisher Scientific introduced a cloud-linked optimization toolkit that integrates in vitro screens with in silico pharmacophore modeling, reducing lead refinement time by 20%. Sponsors frequently invest an additional USD 2-5 million during this stage to avert a USD 50 million Phase II setback, a trade-off that tilts budgets toward late-stage discovery services.

By Technology: AI Platforms Tip the Scales

High-throughput screening delivered 34.27% of technology revenue in 2025, yet growth is tapering as machine-learning triage reduces laboratory throughput pressures. The drug discovery market size tied to AI platforms is projected to grow fastest, with a 9.63% CAGR, more than offsetting incremental cloud compute costs. Bioinformatics and in-silico modeling, 24% of technology spend, now ride on hyperscale infrastructure; AWS released life-sciences-tuned instances that cut molecular-dynamics simulation prices by 40%. Combinatorial chemistry鈥檚 renaissance is evident in DNA-encoded libraries that assign a unique oligonucleotide barcode to each compound, enabling sponsors to screen billions of variants in a single experiment. 

HitGen鈥檚 USD 100 million funding round and DyNAbind鈥檚 USD 45 million infusion in 2024 expanded global DEL capacity. Schr枚dinger鈥檚 physics-based algorithms guided eight pre-clinical candidates to IND filing in 2024, a milestone that elevates virtual screening credibility beyond proof-of-concept. Exscientia dosed a first patient with an AI-designed molecule in 2024, marking a watershed moment for software-led chemistry. These wins cement AI as a defining feature of platform differentiation.

By Drug Type: Biologics Complexity Drives Outsourcing

Small molecules maintained 61.72% of 2025 revenue, anchoring the drug discovery market with advantages in oral absorption and cost of goods. However, biologics and large molecules register the swiftest climb, with an 8.18% CAGR, as antibody-drug conjugates and bispecific formats deliver potent, selective mechanisms. WuXi Biologics confirmed that 78% of its discovery clients are small- to mid-sized firms lacking mammalian cell line know-how. 

Targeted protein degradation blurs modality lines. Arvinas moved three PROTAC candidates into human trials during 2024, while Nurix Therapeutics dosed its first molecular-glue program. The FDA issued draft expectations that demand characterization of both on-target and off-target degradation, elevating the analytical rigor of discovery. As a result, CROs that host proteomics platforms and ubiquitination assays secure long-term master service agreements, ensuring steady demand throughout the forecast window.

By Therapeutic Area: Metabolic Disorders Attract Renewed Capital

Oncology accounted for 27.78% of therapeutic spending in 2025, driven by immuno-oncology and precision approaches that match drugs to biomarkers. Metabolic disorders, however, are forecast to be the fastest mover at an 8.41% CAGR as GLP-1 receptor agonists expand beyond diabetes into obesity, non-alcoholic steatohepatitis, and cardiovascular disease. 

Eli Lilly鈥檚 tirzepatide posted USD 5.2 billion in 2024 sales and helped open additional therapeutic avenues for dual incretin agonists. Novo Nordisk鈥檚 semaglutide generated USD 21 billion the same year, setting a commercial benchmark that shifted venture dollars toward metabolic pipelines. Central nervous system drug discovery remains challenging due to blood-brain barrier hurdles, yet sponsors continue to invest because the unmet need is massive. Cardiovascular programs explore RNA-interference and antisense oligonucleotides on the heels of positive real-world data for inclisiran, while antimicrobial resistance initiatives leverage the FDA鈥檚 QIDP incentives to secure exclusivity extensions.

By End User: CROs Capitalize on the Outsourcing Wave

Pharmaceutical and biotechnology enterprises accounted for 65.08% of end-user revenue in 2025, underscoring the continued dominance of in-house discovery among top-tier sponsors. Contract research organizations, though, are projected to grow by 8.52% and offer a safety valve for companies seeking variable-cost structures. Charles River Laboratories bought Cognate BioServices for USD 875 million to add cell-therapy capabilities and deliver end-to-end packages. 

The NIH鈥檚 NCATS funded 18 such projects in 2024, allocating USD 120 million to help universities advance basic discoveries toward preclinical candidates. WuXi AppTec provides an integrated suite spanning target identification through Phase III clinical supply, while Evotec shares milestone upside in multi-partner deals. The BIOSECURE Act prompted many U.S. sponsors to steer work away from mainland China, opening opportunities for Indian CROs such as Syngene and Jubilant Biosys, each of which posted more than 25% revenue growth in 2024.

Geography Analysis

North America accounted for 43.78% of 2025 revenue in the drug discovery market, driven by venture capital density, a deep talent pool, and proximity to the FDA. Cost inflation plus talent shortages, however, constrain further acceleration and make outsourcing attractive. 

Asia-Pacific is projected to climb at an 11.27% CAGR, the fastest regional clip, driven by India鈥檚 40% to 50% cost advantage and China鈥檚 domestic demand following the BIOSECURE Act sanctions. Indian players hired an additional 2,200 scientists and expanded laboratory space by 1.2 million square feet in 2024 alone. Japan funds biotech innovation hubs that anchor joint academic鈥搃ndustry projects, and Singapore offers tax holidays for biologics investment, strengthening regional competitiveness. 

Regulatory Landscape

Drug discovery programs increasingly face regulator-led expectations on how computational evidence and novel testing methods are generated, governed, and documented. In the European Union, the European Medicines Agency (EMA) finalized its reflection paper on the use of artificial intelligence (AI) and machine learning in the medicinal product lifecycle in September 2024, pushing sponsors to perform risk analyses for AI/ML tools used across R&D and quality activities.

In the United States, the FDA has been formalizing pathways that affect discovery-to-IND packages through guidance and international harmonization. In March 2026, the FDA issued draft guidance on New Approach Methodologies (NAMs) for drug development, covering the validation and use of non-animal approaches such as in silico models and organoid-based methods. In June 2026, the FDA issued the final ICH M15 guidance on Model-Informed Drug Development (MIDD), strengthening a common, globally aligned framework for model planning, evaluation, and documentation. These steps raise the compliance value of traceable data provenance, model credibility assessments, and standardized reporting for sponsors and CRO partners operating across regions.

Market Opportunities and Future Outlook

The clearest near-term opportunity is the build-out of regulated, audit-ready AI and modeling infrastructure that links target identification through preclinical candidate selection, in line with tighter expectations on provenance, credibility, and risk management for AI and NAM-derived evidence. This direction is reinforced by the FDA making its ISTAND pilot program permanent (July 2025), and by 2026 actions that support earlier engagement around modernized development approaches. Vendors that package validated NAM toolchains, secure data pipelines, and documentation services for multi-region filings are positioned to benefit.

Deal activity in 2026 also points to commercial whitespace for platforms that pair discovery engines with modality-specific capabilities, including targeted protein degradation, multispecific biologics, and antibody-drug conjugates. Roche and Nurix Therapeutics announced a global collaboration in June 2026 around a BTK degrader program, and Insilico Medicine and SK Biopharmaceuticals entered an AI-enabled discovery collaboration for neuroimmune disorders in June 2026, reflecting buyer willingness to commit to differentiated discovery approaches at scale. In parallel, the NVIDIA and Eli Lilly co-innovation AI lab announced in January 2026 (up to USD 1 billion over five years), supporting continued demand for scaled compute and curated biomedical datasets, and helping service providers and software platforms package high-throughput and multimodal outputs into regulator-consumable evidence.